< Back to Inductees

Peter Grootenhuis, Ph.D.

Dr. Grootenhuis was Senior Director of Chemistry at Vertex in San Diego. Prior to joining Vertex in 2002, Grootenhuis worked at CombiChem-DuPont in San Diego (1998-2002), and at Organon in the Netherlands (1989-1998). At Vertex, Grootenhuis was research project-leader in the areas of cystic fibrosis and sodium channel blockers. He is co-inventor of several CFTR modulators that entered clinical development including ivacaftor (FDA approved 2012), lumacaftor (FDA approved 2015), tezacaftor (FDA approved 2018), VX-152, VX-440 (phase 2), VX-659, VX-445 (phase 3), and NaV1.7 blocker VX-241 (phase 1).

Grootenhuis received MSc and PhD degrees in chemistry at the Universities of Utrecht and Twente in the Netherlands. Subsequently, he performed post-doctoral studies in computational chemistry at UC San Francisco (1987-1989) under supervision of Prof. Peter Kollman, followed in 1991 by a short sabbatical with Prof. Martin Karplus at Harvard University. He has held part-time professorship positions at the Universities of Groningen, Twente, and the Free University of Amsterdam.

Grootenhuis has published over 100 peer reviewed papers and is inventor of 65 U.S. patents. He received several scientific awards, most recently the 2013 ACS Heroes of Chemistry award and the 2018 IUPAC-Richter Prize in Medicinal Chemistry.

ACS Division of Medicinal Chemistry

Webmaster:  secretary@acsmedchem.org